Lumida
/MIRM
⌘K
Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc

MIRM
$98.22USD-2.38%-2.39 today

MARKET CAP

6.4B

P/E (TTM)

FWD P/E

DAY RANGE

$98 – $103

52W RANGE

$63
$130

AI Summary

Stalk
TrimMedium

Despite long-term upward momentum from the rising 200-day SMA, MIRM is consolidating under the 9/20/50 EMAs without clear pattern. This distribution-phase context yields a medium-term bearish bias, favoring defensive sell-side execution on rallies into the 20/50 EMA zone. Short-term timing remains neutral, calling for patience and trimming exposure at resistance rather than immediate exits.

  • Q2 net product sales increased 37.5% YoY to $176M, reflecting strong execution.
  • Full-year 2026 sales guidance upped to $680–$700M, underscoring management confidence.
  • Negative earnings yield and weak profitability metrics suggest cash-flow risks.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$19.1M$77.1M$186.4M$336.9M$521.3M
YoY %+302.7%+141.8%+80.8%+54.7%
P / Sales25.3x8.5x6.6x5.8x7.6x
EV / Sales32.7x10.9x7.2x6.5x8.1x
Gross Profit, Adj.$17.2M$64.7M$139.3M$255.2M$421.1M
YoY %+275.3%+115.4%+83.2%+65.0%
Margin %90.1%83.9%74.8%75.8%80.8%
EV / Gross Profit36.4x13.0x9.6x8.6x10.0x
EBITDA, Adj.$-172.8M$-128.0M$-98.3M$-64.0M$2.1M
YoY %-66.7%+25.9%+23.2%+34.9%+103.3%
Margin %-903.0%-166.1%-52.8%-19.0%0.4%
EV / EBITDA-3.6x-6.5x-13.6x-34.2x1990.8x
EBIT$-173.4M$-131.2M$-109.2M$-87.6M$-22.1M
YoY %-66.3%+24.3%+16.8%+19.7%+74.7%
Margin %-906.1%-170.3%-58.6%-26.0%-4.2%
EV / EBIT-3.6x-6.4x-12.3x-25.0x-189.6x
Net Income$-84.0M$-135.7M$-163.4M$-87.9M$-23.4M
YoY %+18.7%-61.5%-20.5%+46.2%+73.4%
Net Margin-438.9%-176.0%-87.7%-26.1%-4.5%
EPS (GAAP)-$2.77-$4.02-$4.00-$1.85-$0.47
YoY %+32.3%-45.1%+0.5%+53.8%+74.6%